Codeine-7,8-oxide (codeine epoxide) ( Fig. 1) was recently identified as a new metabolite of codeine (1) . Findings of Takayanagi et al. (2) using electrically stimulated guinea-pig ileum suggested that codeine-7,8-oxide had a potent narcotic analgesic activity as described in the preliminary report of Miyata et al. (3) , and epoxidation of 7,8-double bond of codeine resulted in a trend for a decrease in the dependence liability. Furthermore, Yoshimura and his co-workers (4) (5) (6) found that the antinociceptive actions of morphine-6
glucuronide and morphine-6-sulfate were 2 to 3 times as potent as morphine, while morphine-3-glucuronide, a major metabolite, had no biological activity. In this paper we studied the antinociceptive activity, development of tolerance and the inhibitory activity of abstinence syndrome to clarify pharmacological properties of this new metabolite of codeine.
Antinociceptive activity was measured after subcutaneous injection in the conscious male Wistar rats (80 to 100 g in body weight) with a Randal-Sellito apparatus (Ugo Vasile). Pressure was given to a hind paw and the maximal pressure measured was 250 g.
In order to test development of tolerance in antinociceptive activity, 10 mg/kg of codeine-7,8-oxide or 20 mg/kg of codeine were given subcutaneously every 4 hr for 3 days to male Wistar strain rats (60 to 100 g in body weight).
Antinociceptive activities of both the drugs were measured after every injection. The rats (80 to 100 g) were made dependent on morphine by a daily sub cutaneous injection of morphine.
The dose of morphine was increased during a period of 4 weeks until a daily dose of 80 mg/kg (40 mg/kg twice a day at 10 a.m. and 6 p.m.) : the first week, 20 mg/day, the second week, 40 mg/day, the third week, 60 mg/day and the fourth week, 80 mg/day (7, 8) . The body weight of the treated animals rapidly decreased upon withdrawal, the mean decrease being 24.5±1.5 g (mean±S.E.). After the confirmation of the decrease in body weight upon withdrawal, the animals were further treated with 20 mg/kg of morphine at 10 a.m. and 6 p.m. Next week, the animals were divided into 6 groups of 7 rats. A control was administered saline and the others were used as test groups which were subcutaneously injected with morphine, (Fig. 2) . In the animals treated with either drug more than 7 times, the antinociceptive action of codeine was significantly smaller than that of codeine-7,8 oxide (Fig. 2) .
Decrease in body weight of the rats repeatedly treated with morphine was 23.4±2.6 g (mean±S.E.)
after the injection of saline instead of morphine. When codeine-7,8-oxide (40 mg/kg, s.c.) was injected instead of morphine, the mean decrease of body weight of the rats treated with morphine was 11.2±2.0 g. The body weight was increased with subcutaneous injection of 80 mg/kg of codeine which was equipotent to a dose of 40 mg/kg codeine 7,8-oxide in antinociceptive action, the mean being 3.1±0.9 g. The rats treated with 20 mg/kg morphine lost 1.2±2.3 g, while an increase of body weight was observed with 40 mg/kg morphine, the mean being 6.0 ±0.5 g. The body weight of the 7 rats untreated with morphine increased when saline was injected (Fig. 2) . The results shown in Fig. 2 demonstrate that the development of tolerance is slower in the rats treated with codeine-7,8-oxide than in the rats treated with codeine when either drug was given repeatedly to the rats in an equipotent dose. Decrease in body weight upon withdrawal is one of the most clearly observed compo nents in the narcotic abstinence syndrome. 
